Occulo Holdings

Occulo Holdings' subsidiary is creating next-generation biotherapeutics through engineered immune evasion. Biotherapeutics, including antibodies, enzymes, signaling peptides, and toxins, are revolutionizing disease treatment but carry an inherent risk of triggering harmful immune responses. Occulo's proprietary technology seamlessly integrates advanced computational models, protein design algorithms, protein engineering methodologies, and immunoassay techniques to develop optimized therapeutic candidates with reduced immunogenicity while maintaining functional equivalence or superiority to natural biomolecules.